Skip to main content
Midas Edge

Acrivon Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

ACRV$1.57-0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Common Stock
SharesAmountAdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitTotalStockholders’Equity
Balance at December 31, 202431,231,264$31$373,284$447$(196,976)$176,786
Exercise of common stock options225—1——1
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax120,578—(344)——(344)
Stock-based compensation expense——3,791——3,791
Unrealized loss on available-for-sale investments, net of tax———(164)—(164)
Net loss————(19,680)(19,680)
Balance at March 31, 202531,352,067$31$376,732$283$(216,656)$160,390
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax97,677—(97)——(97)
Stock-based compensation expense——3,927——3,927
Unrealized loss on available-for-sale investments, net of tax———(177)—(177)
Net loss————(21,006)(21,006)
Balance at June 30, 202531,449,744$31$380,562$106$(237,662)$143,037
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax100,026—(117)——(117)
Stock-based compensation expense——3,911——3,911
Unrealized gain on available-for-sale investments, net of tax———6—6
Net loss————(18,234)(18,234)
Balance at September 30, 202531,549,770$31$384,356$112$(255,896)$128,603

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

Common Stock
SharesAmountAdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitTotalStockholders’Equity
Balance at December 31, 202322,522,644$23$237,675$(83)$(116,420)$121,195
Exercise of common stock options20,277—79——79
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax94,618—(166)——(166)
Stock-based compensation expense——3,344——3,344
Unrealized gain on available-for-sale investments, net of tax———13—13
Net loss————(16,486)(16,486)
Balance at March 31, 202422,637,539$23$240,932$(70)$(132,906)$107,979
Issuance of common stock in private placement, net of issuance costs of $3,3608,235,000866,629——66,637
Issuance of pre-funded warrants in private placement, net of issuance costs of $2,881——57,122——57,122
Exercise of common stock options10,598—11——11
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax83,118—(510)——(510)
Stock-based compensation expense——3,566——3,566
Unrealized gain on available-for-sale investments, net of tax———51—51
Net loss————(18,798)(18,798)
Balance at June 30, 202430,966,255$31$367,750$(19)$(151,704)$216,058
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax164,637—(1,197)——(1,197)
Stock-based compensation expense——3,671——3,671
Unrealized gain on available-for-sale investments, net of tax———801—801
Net loss————(22,441)(22,441)
Balance at September 30, 202431,130,892$31$370,224$782$(174,145)$196,892
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.